Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03013491 · ClinicalTrials.gov registry record · Phase 1
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
A Phase 1 study, sponsored by CytomX Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 196
- Enrollment target
NCT03013491 is a Phase 1 study that was terminated before completion, run by CytomX Therapeutics. The registered enrollment target is 196 participants.
The verdict
NCT03013491, a Phase 1 study, was terminated before completion, sponsored by CytomX Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 196 participants
- Enrollment target
Study Summary
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with advanced or recurrent solid tumors or lymphomas. PROCLAIM-CX-072: PRObody CLinical Assessment In Man CX-072 clinical trial CX-072 is a Probody® therapeutic directed against PD-L1 (programmed cell death ligand 1). Probody therapeutics are proteolytically-activatable antibodies (Abs) designed to widen the therapeutic index by minimizing drug interaction with normal tissue while retaining anti-tumor activity. Probody therapeutics are "masked" to attenuate binding to target in healthy tissue but can become "unmasked" in the tumor microenvironment by tumor-specific protease activity. PROBODY is a U.S. registered trademark of CytomX Therapeutics, Inc.
Interventions
- DRUG ipilimumab
- DRUG vemurafenib
- DRUG CX-072
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2017-01-19 |
| Est. Completion | 2020-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03013491
The ClinicalTrials.gov registry entry for NCT03013491 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytomX Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ipilimumab is the first listed.
NCT03013491 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03013491 about?
NCT03013491 is a clinical study titled "PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas". The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with adva...
What is the current status of trial NCT03013491?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 196 participants. The study started on 2017-01-19. Estimated completion is 2020-10-27.
What interventions are being tested in trial NCT03013491?
The interventions under investigation include: ipilimumab (DRUG), vemurafenib (DRUG), CX-072 (DRUG).
Who is sponsoring clinical trial NCT03013491?
This trial is sponsored by CytomX Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.